Caliway Biopharmaceuticals C, TW0006919004

Caliway advances CBL-514 to phase 3 for Caliway Biopharmaceuticals C stock

Published on 10/26/2026 at 09:02 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

CBL-514 cut visceral fat 12.01 percent; 69.60 percent met the threshold. Caliway Biopharmaceuticals C stock enters a 320-person phase 3 program.

Clinical program and trading context

CBL-514 data showed a 69.60 percent response on October 2, 2026.
Visceral fat fell 12.01 percent against a 5.68 percent placebo increase in phase 2.
Caliway Biopharmaceuticals C stock was last at TWD 73.80 on October 22, 2026.

Caliway Biopharmaceuticals C, TW0006919004, Illustration mit AI erstellt.

Caliway Biopharmaceuticals is advancing its experimental CBL-514 injection into phase 3 after clinical data showed a 69.60 percent response among treated participants. Pharmaphorum reported the development on October 25, 2026, highlighting CBL-514's phase 2 results and planned pivotal studies.

Three milestones frame the program

The recent sequence began on September 23, 2026, when the first participant was dosed in SUPREME-01, a phase 3 study planned to enroll 320 people, according to the CBL-514 research page. On October 2, 2026, Caliway Biopharmaceuticals published EASD data showing that 69.60 percent of treated participants reduced subcutaneous fat by at least 150 milliliters at eight weeks, versus 0 percent in the placebo group. The October 25, 2026 Pharmaphorum report then described the phase 3 transition.

What does the fat result show?

The key comparison is visceral fat rather than the cosmetic endpoint alone. The official company release said average visceral fat fell 12.01 percent four weeks after treatment in the CBL-514 group, while the placebo group rose 5.68 percent, a 17.69 percentage-point difference.

The same analysis found that visceral fat remained 10.45 percent below baseline at the later follow-up, while the placebo group was 11.76 percent above baseline. The results came from phase 2 studies CBL-0204 and CBL-0205, with MRI data from 41 participants and follow-up data for 40. The small sample makes the phase 3 readout the next important test of reproducibility.

Next dates for the clinical program

SUPREME-01 is scheduled for estimated primary completion in July 2027 and overall study completion in September 2027, according to the CBL-514 research page. Those dates define the planned study timeline, while the October 2, 2026 release said the first results from the phase 3 program were expected at the end of 2027.

Stock valuation remains clinical

Caliway Biopharmaceuticals shares were last at TWD 73.80 on October 22, 2026, on the Taiwan Stock Exchange. The same dated market page listed a 52-week range of TWD 73.80 to TWD 188.00, leaving clinical execution as the central company-specific valuation factor.